Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company's lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California. Show more

Location: 2533 South Coast Highway 101, Cardiff, CA, 92007, United States | Website: https://www.viracta.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

397.4K

52 Wk Range

$0.01 - $0.58

Previous Close

$0.01

Open

$0.01

Volume

228,329

Day Range

$0.01 - $0.01

Enterprise Value

-3.56M

Cash

21.13M

Avg Qtr Burn

-8.699M

Insider Ownership

2.99%

Institutional Own.

21.22%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nana-val (Nanatinostat (VRx-3996) (histone deacetylase (HDAC) inhibitor) + valganciclovir) Details Solid tumor/s, Cancer, Nasopharyngeal carcinoma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nana-val (nanatinostat + valganciclovir) Details Cancer, Diffuse large B cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nana-val (nanatinostat + valganciclovir) Details Cancer, Lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.